Analysis of P-Selectin Expression on Platelets of Blood From Lung Cancer Patients

NCT02758678 | Completed

• 2 other identifiers: Science and Technology Park,2/07/2015
• Study Type: observational
• Target: 40
• Locations: 1 country
• Sites: 1

Brief Summary

Purpose: Selectins are vascular cell adhesion molecules involved in adhesive interactions of leukocytes and platelets and endothelium within the blood circulation. Plasma soluble P selectin (sP-selectin), is a one of member of selectin family, an adhesion molecule and component of the membrane of the platelet alpha granulate has been proposed as a one marker of platelet activation. In this study we evaluate of expression of P selectin on platelets of blood between serum samples from lung cancer and healthy individuals.

Conditions

Lung Cancer

Keywords

P-selectin; Lung Cancer; Raman Spectroscopy

Outcome Measures

Primary Outcomes (1)

• Assessment of the concentration of P-selectin in 3 groups in lung cancer patients and compared to the healthy participants.

  Assessment of the concentration of P-selectin in 3 groups in lung cancer patients and compare the concentration of P-selectin depends on tumor volume.Comparison between 3 groups and in the end, compared to the healthy population

  The study started from November 2015 and will be completed in May 2016. The end of the study will be July 2016.Data will be presented up to 1 year.

Study Arms (3)

1-patients with operating tumor

1- 23 patients with operating tumor; In 1 group the specimens of blood will be collected day before surgery and 1-2 month after surgery. Will be collected: histopathology outcomes - type carcinoma, tumore volume and before surgery: morphology and coagulation system. Will be assessed correlation between mentioned above factors and concentration of P-selectin. Will be compared concentration of P-selectin in 3 groups of patients. Serum separation and Raman spectroscopy analysis. A single 2 ml heparinised peripheral blood sample was centrifuges to get serum specimens. The Raman spectra (RS) of the solid residues from serum samples were measurement by placing 10µl of serum from the aliquots onto an aluminium substrate and allowed to dry for at least 30 min.

Biological: A single 2 ml heparinised peripheral blood sample

2-patients with advanced desease.

2- ten patients with advanced and metastatic disease who received palliative RT (RT - radiotherapy); In 2 group - the specimens of blood we collected before palliative treatment-radiotherapy. Will be collected: histopathology outcomes - type carcinoma, morphology. Will be assessed correlation between mentioned factors and concentration of P-selectin. Will be compared concentration of P-selectin in 3 groups of patients. Serum separation and Raman spectroscopy analysis: A single 2 ml heparinised peripheral blood sample was centrifuges to get serum specimens.The Raman spectra (RS) assessed as above

Biological: A single 2 ml heparinised peripheral blood sample

3-patients with inoperable disease

In group 3 - the specimens of blood we collected before radical treatment and one month after completion treatment. Will be collected: histopathology outcomes - type carcinoma, morphology. Will be assessed correlation between mentioned above factors and concentration of P-selectin. Will be compared concentration of P-selectin in 3 groups of patients. Serum separation and Raman spectroscopy analysis: A single 2 ml heparinised peripheral blood sample was centrifuges to get serum specimens. The Raman spectra (RS) of the solid residues from serum samples were measurement by placing 10µl of serum from the aliquots onto an aluminium substrate and allowed to dry for at least 30 min.

Biological: A single 2 ml heparinised peripheral blood sample

Interventions

A single 2 ml heparinised peripheral blood sample BIOLOGICAL

A single 2 ml heparinised peripheral blood sample was centrifuges to get serum specimens. Serum separation and Raman spectroscopy analysis:

1-patients with operating tumor; 2-patients with advanced desease.; 3-patients with inoperable disease

Eligibility Criteria

• Age: 40 Years - 80 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

both female and male participants are being studied with confirmed lung cancer

You may qualify if:

• confirmed lung cancer
• WHO 0-2
• month after chemotherapy in palliative patients

You may not qualify if:

• double cancer
• another cancer
• chemotherapy in radical patients
• prior external beam radiation in an interview with the patient

Sponsors & Collaborators

• Science and Technology Park, Center of Innovation Technologies for Human Health: lead
• University in Zielona Góra: collaborator

Study Sites (1)

Park Naukowo-Technologiczny Uniwersytetu Zielonogórskiego Sp. z o.o.

Zielona Góra, Lubusz Voivodeship, 65-417, Poland

Location

Related Publications (2)

• Blann AD, Lip GY. Hypothesis: is soluble P-selectin a new marker of platelet activation? Atherosclerosis. 1997 Feb 10;128(2):135-8. doi: 10.1016/s0021-9150(96)05980-1. No abstract available.

  PMID: 9050769 BACKGROUND

• Bendas G, Borsig L. Cancer cell adhesion and metastasis: selectins, integrins, and the inhibitory potential of heparins. Int J Cell Biol. 2012;2012:676731. doi: 10.1155/2012/676731. Epub 2012 Feb 12.

  PMID: 22505933 BACKGROUND

Biospecimen

Retention: SAMPLES WITHOUT DNA

A single 2 ml heparinised peripheral blood sample was centrifuges to get serum

MeSH Terms

Conditions

Lung Neoplasms

Condition Hierarchy (Ancestors)

Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases

Study Officials

• Edyta I Wolny-Rokicka, MD.PhD

  Clinicial Hospital in Zielona Góra,Radiotherapy Department ul Zyty 26, Zielona Góra, Poland

  STUDY CHAIR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: INDUSTRY
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: MD PhD

Study Record Dates

• First Submitted: April 18, 2016
• First Posted: May 2, 2016
• Study Start: November 1, 2015
• Primary Completion: October 1, 2016
• Study Completion: October 1, 2016
• Last Updated: October 19, 2016

Record last verified: 2016-10

Data Sharing

• IPD Sharing: Will share

Locations

PL (1)